BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 27413814)

  • 1. A case of TAFRO syndrome, a variant of multicentric Castleman's disease, successfully treated with corticosteroid and cyclosporine A.
    Takasawa N; Sekiguchi Y; Takahashi T; Muryoi A; Satoh J; Sasaki T
    Mod Rheumatol; 2019 Jan; 29(1):198-202. PubMed ID: 27413814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A : a case report.
    Inoue M; Ankou M; Hua J; Iwaki Y; Hagihara M; Ota Y
    J Clin Exp Hematop; 2013; 53(1):95-9. PubMed ID: 23801140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological findings of progressive renal involvement in a patient with TAFRO syndrome.
    Saito H; Tanaka K; Fujiwara M; Iwasaki T; Numata T; Oda A; Kanno M; Tanaka M; Eiro M; Satoh M; Kazama JJ
    CEN Case Rep; 2019 Nov; 8(4):239-245. PubMed ID: 31077056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Treatment with Cyclosporin A in Tocilizumab-resistant TAFRO Syndrome.
    Yamaga Y; Tokuyama K; Kato T; Yamada R; Murayama M; Ikeda T; Yamakita N; Kunieda T
    Intern Med; 2016; 55(2):185-90. PubMed ID: 26781021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAFRO syndrome successfully treated with tocilizumab: A case report and systematic review.
    Sakai K; Maeda T; Kuriyama A; Shimada N; Notohara K; Ueda Y
    Mod Rheumatol; 2018 May; 28(3):564-569. PubMed ID: 26886414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Treatment of TAFRO Syndrome, a Variant of Multicentric Castleman's Disease, with Cyclosporine A: Possible Pathogenetic Contribution of Interleukin-2.
    Konishi Y; Takahashi S; Nishi K; Sakamaki T; Mitani S; Kaneko H; Mizutani C; Ukyo N; Hirata H; Tsudo M
    Tohoku J Exp Med; 2015 Aug; 236(4):289-95. PubMed ID: 26250536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High proportion of TAFRO syndrome in Thai adult Castleman's disease patients: a 10-year experience.
    Owattanapanich W; Pholmoo W; Pongpruttipan T; Siritanaratkul N
    Ann Hematol; 2018 Jun; 97(6):1019-1026. PubMed ID: 29464312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia--a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity?
    Masaki Y; Nakajima A; Iwao H; Kurose N; Sato T; Nakamura T; Miki M; Sakai T; Kawanami T; Sawaki T; Fujita Y; Tanaka M; Fukushima T; Okazaki T; Umehara H
    J Clin Exp Hematop; 2013; 53(1):79-85. PubMed ID: 23801138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffuse Large B-cell Lymphoma during Corticosteroid Therapy for TAFRO Syndrome.
    Ohya E; Mizutani M; Sakaguchi H; Sekine T
    Intern Med; 2016; 55(19):2861-2867. PubMed ID: 27725549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successfully treated multicentric Castleman's disease with renal thrombotic microangiopathy using rituximab and corticosteroid.
    Lee JP; Kim DK; Oh DY; Paik JH; Moon KC; Kim S; Kim YS
    Clin Nephrol; 2011 Feb; 75(2):165-70. PubMed ID: 21255547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adrenalitis and anasarca in idiopathic multicentric Castleman's disease.
    Chen LYC; Skinnider BF; Wilson D; Fajgenbaum DC
    Lancet; 2021 May; 397(10286):1749. PubMed ID: 33965090
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute Kidney Injury Caused by TAFRO Syndrome in a Chinese Patient: Efficacy of Long-Term Corticosteroids Combined with Bortezomib and Cyclophosphamide.
    Xia P; Zhang L; Zou M; Zhang T; Li R; Shi X; Wang J; Qin Y; Li X; Li J; Chen L
    Kidney Blood Press Res; 2020; 45(4):623-630. PubMed ID: 32492687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody.
    Kawabata H; Kotani S; Matsumura Y; Kondo T; Katsurada T; Haga H; Kadowaki N; Takaori-Kondo A
    Intern Med; 2013; 52(13):1503-7. PubMed ID: 23812199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [TAFRO syndrome and monoclonal gammapathy: Uncommon association!].
    Naifar M; Messedi M; Elleuch A; Snoussi M; Gouiaa N; Turki M; Lahiani A; Boudawara T; Bahloul Z; Ayedi F
    Curr Res Transl Med; 2016; 64(1):43-7. PubMed ID: 27140598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recovery from prolonged thrombocytopenia in patients with TAFRO syndrome: case series and literature review.
    Yamaguchi Y; Maeda Y; Shibahara T; Nameki S; Nakabayashi A; Komuta K; Mizuno Y; Yagita M; Manabe Y; Morita T; Nishide M; Watanabe A; Takamatsu H; Nishida S; Hirano T; Shima Y; Narazaki M; Kumanogoh A
    Mod Rheumatol Case Rep; 2020 Jul; 4(2):302-309. PubMed ID: 33087016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study.
    Zhang Y; Suo SS; Yang HJ; Zhou XP; You LS; Yu WJ; Wang ZM; Jin J
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):357-365. PubMed ID: 31938902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HHV-8-positive Castleman's disease with rapidly progressing multiorgan failure mimicking TAFRO syndrome].
    Ide S; Ohara S; Uchida T; Inoue M; Hagihara M
    Rinsho Ketsueki; 2020; 61(10):1497-1501. PubMed ID: 33162447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical hyaline vascular-type castleman's disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy.
    Iwaki N; Sato Y; Takata K; Kondo E; Ohno K; Takeuchi M; Orita Y; Nakao S; Yoshino T
    J Clin Exp Hematop; 2013; 53(1):87-93. PubMed ID: 23801139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report.
    Tedesco S; Postacchini L; Manfredi L; Goteri G; Luchetti MM; Festa A; Gabrielli A; Pomponio G
    Exp Hematol Oncol; 2015; 4(1):3. PubMed ID: 25671135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Siltuximab Monotherapy in Tafro Syndrome: A Case Report and Review of the Literature.
    Cordero L; Aguilar-Rodríguez F; Sandino J; Alonso M; Gutiérrez E
    J Nephrol; 2023 May; 36(4):1181-1185. PubMed ID: 36652167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.